|View printer-friendly version|
|January 30, 2006 1:27 p.m.|
|Teva Announces Global In-Market Fourth Quarter Sales of Its Blockbuster Copaxone® Increased 24% to $323 Million|
Annual Sales Increased 26% to Record $1.18 Billion
Jerusalem, Israel, January 30, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached $323 million in the fourth quarter ended December 31, 2005, an increase of 24% over the comparable quarter of 2004. For the full year 2005, global in-market sales of Copaxone® reached an all-time high of $1,176 million, an increase of 26% over 2004.